Skin Cancer Diagnostics Using Photoacoustic Imaging

Skin Cancer Clinical Trial

Official title:

Photoacoustic Imaging for Three-dimensional Delineation of Skin Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06379581
• Other study ID #: 2022-04900-02
• Status: Recruiting
• Start date: January 1, 2023
• Est. completion date: October 1, 2025

Study information

• Verified date: April 2024
• Source: Region Skane
• Contact: John Albinsson, PhD
• Phone: 0702497057
• Email: john.albinsson[@]med.lu.se
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this clinical study, photoacoustic imaging will be used on patients with suspected skin cancer (primarily melanoma, basal cell carcinoma, and squamous cell carcinoma) to determine the tumor borders both superficially and at a depth.

Description:

The study will employ multispectral photoacoustic imaging in the spectral range between 680-970 nm to scan suspected skin tumors both in vivo and ex vivo. The hyperspectral data will then undergo rigorous spectral analysis with the objective to identify the spectral fingerprints associated with healthy tissue and tumor. Thereafter, a classification algorithm will be used to determine whether a pixel in the acquired image more likely identifies with healthy tissue or tumor, which is then repeated for all pixels in the images. As such, a 3D image can be reconstructed in which the tumor is visibly contrasted from healthy tissue. Achieving this goal will facilitate the diagnostic procedures and greatly reduce waiting times, clinical costs and potential patient suffering.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: October 1, 2025
• Est. primary completion date: October 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients scheduled to perform surgical excision of lesion(s) suspected to be tumors.

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Skin Cancer
• Skin Neoplasms

Locations

Country	Name	City	State
Sweden	Department of Ophthamology, Lund, Skåne University Hospital	Lund

Sponsors (2)

Lead Sponsor	Collaborator
Region Skane	Lund University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor thickness	Compare the estimated tumor thickness of tumor lesion with the provided thickness from the histopathological investigation.	Enrollment is anticipated to last 1 year + final analyse 6 months
Primary	Tumor size	Compare the estimated tumor surface size of tumor lesion with the provided thickness from the histopathological investigation.	Enrollment is anticipated to last 1 year + final analyse 6 months